Pemvidutide (ALT-801)
Obesity
About Altimmune
Altimmune leverages its proprietary peptide technology platform to design multi-targeted agonists that address complex metabolic disorders. The company's most advanced program, pemvidutide, has demonstrated promising weight loss and liver fat reduction in clinical studies, positioning it in the competitive but high-value obesity and MASH markets. Altimmune's strategy is to advance pemvidutide through clinical development, potentially seeking partnerships for later-stage trials and commercialization. The company operates as a lean, research-focused organization with key expertise in peptide chemistry and metabolic disease.
View full company profileAbout Altimmune
Altimmune leverages its proprietary peptide technology platform to design multi-targeted agonists that address complex metabolic disorders. The company's most advanced program, pemvidutide, has demonstrated promising weight loss and liver fat reduction in clinical studies, positioning it in the competitive but high-value obesity and MASH markets. Altimmune's strategy is to advance pemvidutide through clinical development, potentially seeking partnerships for later-stage trials and commercialization. The company operates as a lean, research-focused organization with key expertise in peptide chemistry and metabolic disease.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Zepbound) | Eli Lilly | Approved |
| APJ Program | BioAge Labs | Preclinical |
| Wegovy HD (semaglutide 7.2mg) | Novo Nordisk | Approved |
| Amylin analogue (subcutaneous) | Novo Nordisk | Phase 1 |
| GLP1-GIP-Amylin tri-agonist | Novo Nordisk | Phase 2 |
| VK2735 (subcutaneous) | Viking Therapeutics | Phase 3 |
| VK2735 (oral) | Viking Therapeutics | Phase 1/2 |
| GSBR-1290 | Structure Therapeutics | Phase 2 |
| LTSE-2578 | Structure Therapeutics | Preclinical |
| Survodutide (BI 456906) | Zealand Pharma | Phase 3 |
| ZP8396 | Zealand Pharma | Preclinical/Phase 1 |
| PL7737 | Palatin Technologies | Preclinical |